论文部分内容阅读
目的 :探讨SDZPSC 833和维拉帕米 (Verapamil,VER)对MMC体外增敏作用。方法 :以人宫颈癌Hela细胞和耐药亚系Hela/MMC细胞为材料 ,观察了PSC 833和VER对MMC体外增敏作用。结果 :无毒剂量的PSC 833和VER (1～ 3μg/ml)可显著增加MMC的细胞毒作用且可基本克服Hela/MMC细胞对MMC 5倍的耐药 ,3 H_TdR实验表明 ,VER或PSC 833与MMC联用可增加MMC对宫颈癌细胞DNA合成的抑制 ,且PSC作用强于VER ,光镜和电镜下形态学观察 ,联合用药组细胞呈明显退行性变。结论 :无毒剂量的PSC 833和VER体外能基本逆转Heal/MMC细胞对MMC的耐药性 ,且PSC 833作用强于VER ,PSC 833作为耐药修饰剂可望用于宫颈癌化疗 ,其临床应用前景优于VER。
Objective: To investigate the sensitization effect of SDZPSC 833 and verapamil (VER) to MMC in vitro. Methods: Human cervical carcinoma Hela cells and Hela / MMC cells were used as materials to observe the sensitization effect of PSC 833 and VER to MMC in vitro. Results: Non-toxic doses of PSC 833 and VER (1-3 μg / ml) significantly increased the cytotoxicity of MMC and overcame the resistance of Hela / MMC cells by 5-fold. The 3 H-TdR assay showed that VER or PSC 833 In combination with MMC, MMC could inhibit the DNA synthesis of cervical cancer cells, and the effect of PSC was stronger than that of VER. The morphological observation under light and electron microscope showed that the cells in combination group showed obvious degenerative changes. Conclusion: Non-toxic doses of PSC 833 and VER can basically reverse the drug resistance of Heal / MMC cells to MMC, and the effect of PSC 833 is stronger than that of VER. PSC 833 is expected to be used as a drug-resistant modifier in cervical cancer chemotherapy. Application is better than VER.